Previous 10 | Next 10 |
Mindmed Announces Voting Results for Annual General and Special Meeting Canada NewsWire NEW YORK , June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's ...
MindMed to Participate in the Jefferies Global Healthcare Conference Canada NewsWire NEW YORK , June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company develo...
Penny stocks are shares of companies trading for less than $5. They are some of the most volatile assets in the stock market today, but they are also some of the most rewarding if you know what you’re doing. Trading penny stocks is a skill that many retail traders have sought...
ATAI has a large portfolio of drugs, mainly psychedelics, that can be used to treat mental health conditions when other options have failed. There is ample room for new drug developments in this space, given that R&D for new drug developments has been declining. Success depend...
Mind Medicine (NASDAQ:MNMD) appoints Schond L. Greenway as CFO. Mr. Greenway joins MindMed after serving as CFO of Avalo Therapeutics and has over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences se...
MindMed Appoints Schond L. Greenway as Chief Financial Officer Canada NewsWire NEW YORK , May 23, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developin...
Mind Medicine (MindMed) (NASDAQ:MNMD) said its opioid withdrawal therapy MM-110 showed safety in an early stage study in healthy people. The phase 1 trial, which enrolled 108 people, was conducted at a single site in Perth, Australia. Out of 72 people, 51 received up to 325-mg of MM-110 ...
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal Canada NewsWire - Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing sup...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) reported its financial results for the first quarter ending March 31, 2022 . At this time, MindMed does not have any revenue to report. The net and comprehensive loss for the quarter was $18.5 million , ...
MindMed Announces At-The-Market Offering Canada NewsWire NEW YORK , May 16, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health ...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corpo...
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...